45 results on '"Ewert, Ralf"'
Search Results
2. Metabolic cost of unloading pedalling in different groups of patients with pulmonary hypertension and volunteers.
- Author
-
Ittermann, Till, Kaczmarek, Sabine, Obst, Anne, Könemann, Raik, Bahls, Martin, Dörr, Marcus, Stubbe, Beate, Heine, Alexander, Habedank, Dirk, and Ewert, Ralf
- Subjects
PULMONARY hypertension ,HYPERTENSION ,LOADING & unloading ,VOLUNTEERS - Abstract
Recently, the parameter internal work (IW) has been introduced as change in oxygen uptake (VO
2 ) between resting and unloading workload in cardiopulmonary exercise testing (CPET). The proportional IW (PIW) was defined as IW divided by VO2 at peak exercise. A second option is to calculate the PIW based on the workload [PIW (Watt)] by considering the aerobic efficiency. The aim of our study was to investigate whether IW and PIW differ between patients with and without pulmonary hypertension and healthy controls. Our study population consisted of 580 patients and 354 healthy controls derived from the Study of Health in Pomerania. The PIW was slightly lower in patients (14.2%) than in healthy controls (14.9%; p = 0.030), but the PIW (Watt) was higher in patients (18.0%) than in the healthy controls (15.9%; p = 0.001). Such a difference was also observed, when considering only the submaximal workload up to the VAT (19.8% in patients and 15.1% in healthy controls; p < 0.001). Since the PIW (Watt) values were higher in patients with pulmonary hypertension, this marker may serve as a useful CPET parameter in clinical practice. In contrast to most of the currently used CPET parameters, the PIW does not require a maximal workload for the patient. Further studies are needed to validate the prognostic significance of the PIW. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
3. MR-proADM Predicts Exercise Capacity and Survival Superior to Other Biomarkers in PH
- Author
-
Kolditz, Martin, Seyfarth, Hans-Jürgen, Wilkens, Heinrike, Ewert, Ralf, Bollmann, Tom, Dinter, Christiane, Hertel, Sabine, Klose, Hans, Opitz, Christian, Grünig, Ekkehard, Höffken, Gert, and Halank, Michael
- Published
- 2015
- Full Text
- View/download PDF
4. Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis.
- Author
-
Hoeper, Marius M, Dwivedi, Krit, Pausch, Christine, Lewis, Robert A, Olsson, Karen M, Huscher, Doerte, Pittrow, David, Grünig, Ekkehard, Staehler, Gerd, Vizza, Carmine Dario, Gall, Henning, Distler, Oliver, Opitz, Christian, Gibbs, John Simon R, Delcroix, Marion, Park, Da-Hee, Ghofrani, Hossein Ardeschir, Ewert, Ralf, Kaemmerer, Harald, and Kabitz, Hans-Joachim
- Subjects
PULMONARY arterial hypertension ,PULMONARY hypertension ,LUNG diseases ,HYPERTENSION ,CARBON monoxide - Abstract
Among patients meeting diagnostic criteria for idiopathic pulmonary arterial hypertension (IPAH), there is an emerging lung phenotype characterised by a low diffusion capacity for carbon monoxide (DLCO) and a smoking history. The present study aimed at a detailed characterisation of these patients. We analysed data from two European pulmonary hypertension registries, COMPERA (launched in 2007) and ASPIRE (from 2001 onwards), to identify patients diagnosed with IPAH and a lung phenotype defined by a DLCO of less than 45% predicted and a smoking history. We compared patient characteristics, response to therapy, and survival of these patients to patients with classical IPAH (defined by the absence of cardiopulmonary comorbidities and a DLCO of 45% or more predicted) and patients with pulmonary hypertension due to lung disease (group 3 pulmonary hypertension). The analysis included 128 (COMPERA) and 185 (ASPIRE) patients with classical IPAH, 268 (COMPERA) and 139 (ASPIRE) patients with IPAH and a lung phenotype, and 910 (COMPERA) and 375 (ASPIRE) patients with pulmonary hypertension due to lung disease. Most patients with IPAH and a lung phenotype had normal or near normal spirometry, a severe reduction in DLCO, with the majority having no or a mild degree of parenchymal lung involvement on chest computed tomography. Patients with IPAH and a lung phenotype (median age, 72 years [IQR 65–78] in COMPERA and 71 years [65–76] in ASPIRE) and patients with group 3 pulmonary hypertension (median age 71 years [65–77] in COMPERA and 69 years [63–74] in ASPIRE) were older than those with classical IPAH (median age, 45 years [32–60] in COMPERA and 52 years [38–64] in ASPIRE; p<0·0001 for IPAH with a lung phenotype vs classical IPAH in both registries). While 99 (77%) patients in COMPERA and 133 (72%) patients in ASPIRE with classical IPAH were female, there was a lower proportion of female patients in the IPAH and a lung phenotype cohort (95 [35%] COMPERA; 75 [54%] ASPIRE), which was similar to group 3 pulmonary hypertension (336 [37%] COMPERA; 148 [39%] ASPIRE]). Response to pulmonary arterial hypertension therapies at first follow-up was available from COMPERA. Improvements in WHO functional class were observed in 54% of patients with classical IPAH, 26% of patients with IPAH with a lung phenotype, and 22% of patients with group 3 pulmonary hypertension (p<0·0001 for classical IPAH vs IPAH and a lung phenotype, and p=0·194 for IPAH and a lung phenotype vs group 3 pulmonary hypertension); median improvements in 6 min walking distance were 63 m, 25 m, and 23 m for these cohorts respectively (p=0·0015 for classical IPAH vs IPAH and a lung phenotype, and p=0·64 for IPAH and a lung phenotype vs group 3 pulmonary hypertension), and median reductions in N-terminal-pro-brain-natriuretic-peptide were 58%, 27%, and 16% respectively (p=0·0043 for classical IPAH vs IPAH and a lung phenotype, and p=0·14 for IPAH and a lung phenotype vs group 3 pulmonary hypertension). In both registries, survival of patients with IPAH and a lung phenotype (1 year, 89% in COMPERA and 79% in ASPIRE; 5 years, 31% in COMPERA and 21% in ASPIRE) and group 3 pulmonary hypertension (1 year, 78% in COMPERA and 64% in ASPIRE; 5 years, 26% in COMPERA and 18% in ASPIRE) was worse than survival of patients with classical IPAH (1 year, 95% in COMPERA and 98% in ASPIRE; 5 years, 84% in COMPERA and 80% in ASPIRE; p<0·0001 for IPAH with a lung phenotype vs classical IPAH in both registries). A cohort of patients meeting diagnostic criteria for IPAH with a distinct, presumably smoking-related form of pulmonary hypertension accompanied by a low DLCO, resemble patients with pulmonary hypertension due to lung disease rather than classical IPAH. These observations have pathogenetic, diagnostic, and therapeutic implications, which require further exploration. COMPERA is funded by unrestricted grants from Acceleron, Bayer, GlaxoSmithKline, Janssen, and OMT. The ASPIRE Registry is supported by Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study.
- Author
-
Valerio, Luca, Mavromanoli, Anna C, Barco, Stefano, Abele, Christina, Becker, Dorothea, Bruch, Leonhard, Ewert, Ralf, Faehling, Martin, Fistera, David, Gerhardt, Felix, Ghofrani, Hossein Ardeschir, Grgic, Aleksandar, Grünig, Ekkehard, Halank, Michael, Held, Matthias, Hobohm, Lukas, Hoeper, Marius M, Klok, Frederikus A, Lankeit, Mareike, and Leuchte, Hanno H
- Subjects
PULMONARY embolism ,PULMONARY hypertension ,THROMBOEMBOLISM ,CONFIDENCE intervals - Abstract
Aims To systematically assess late outcomes of acute pulmonary embolism (PE) and to investigate the clinical implications of post-PE impairment (PPEI) fulfilling prospectively defined criteria. Methods and results A prospective multicentre observational cohort study was conducted in 17 large-volume centres across Germany. Adult consecutive patients with confirmed acute symptomatic PE were followed with a standardized assessment plan and pre-defined visits at 3, 12, and 24 months. The co-primary outcomes were (i) diagnosis of chronic thromboembolic pulmonary hypertension (CTEPH), and (ii) PPEI, a combination of persistent or worsening clinical, functional, biochemical, and imaging parameters during follow-up. A total of 1017 patients (45% women, median age 64 years) were included in the primary analysis. They were followed for a median duration of 732 days after PE diagnosis. The CTEPH was diagnosed in 16 (1.6%) patients, after a median of 129 days; the estimated 2-year cumulative incidence was 2.3% (1.2–4.4%). Overall, 880 patients were evaluable for PPEI; the 2-year cumulative incidence was 16.0% (95% confidence interval 12.8–20.8%). The PPEI helped to identify 15 of the 16 patients diagnosed with CTEPH during follow-up (hazard ratio for CTEPH vs. no CTEPH 393; 95% confidence interval 73–2119). Patients with PPEI had a higher risk of re-hospitalization and death as well as worse quality of life compared with those without PPEI. Conclusion In this prospective study, the cumulative 2-year incidence of CTEPH was 2.3%, but PPEI diagnosed by standardized criteria was frequent. Our findings support systematic follow-up of patients after acute PE and may help to optimize guideline recommendations and algorithms for post-PE care. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Standard PAH therapy improves long term survival in CTEPH patients
- Author
-
Seyfarth, Hans-Juergen, Halank, Michael, Wilkens, Heinrike, Schäfers, Hans-Joachim, Ewert, Ralf, Riedel, Martin, Schuster, Ernst, Pankau, Hans, Hammerschmidt, Stefan, and Wirtz, Hubert
- Published
- 2010
- Full Text
- View/download PDF
7. Comparison between thermodilution and Fick methods for resting and exercise‐induced cardiac output measurement in patients with chronic dyspnea.
- Author
-
Desole, Susanna, Obst, Anne, Habedank, Dirk, Opitz, Christian F., Knaack, Christine, Hortien, Franziska, Heine, Alexander, Stubbe, Beate, and Ewert, Ralf
- Subjects
CARDIAC output ,DYSPNEA ,PULMONARY hypertension ,CYCLING ,HEMODYNAMICS - Abstract
Studies comparing thermodilution (TD) and the direct Fick method (dFM) for cardiac output (CO) measurement are rare. We compared CO measurements between TD (2–5 cold water injections), the dFM, and indirect Fick method (iFM) at rest and during exercise, and assessed the effect of averaging different numbers of TD measurements during exercise. This retrospective study included 300 patients (52.3% women, mean age 66 ± 11 years) having pulmonary hypertension (76.0%) or unexplained dyspnea. Invasive hemodynamic and gas exchange parameters were measured at rest (supine; n = 300) and during unloaded cycling (semi‐supine; n = 275) and 25‐W exercise (semi‐supine; n = 240). All three methods showed significant differences in CO measurement (ΔCO) at rest (p ≤ 0.001; ΔCO > 1 L/min: 45.0% [iFM vs. dFM], 42.0% [iFM vs. TD], and 45.7% [TD vs. dFM]). ΔCO (TD vs. dFM) was significant during unloaded cycling (p < 0.001; ΔCO > 1 L/min: 56.6%) but not during 25‐W exercise (p = 0.137; ΔCO > 1 L/min: 52.8%). ΔCO (TD vs. dFM) during 25‐W exercise was significant when using one or two (p ≤ 0.01) but not three (p = 0.06) TD measurements. Mean ΔCO (TD [≥3 measurements] vs. dFM) was −0.43 ± 1.98 and −0.06 ± 2.29 L/min during unloaded and 25‐W exercise, respectively. Thus, TD and dFM CO measurements are comparable during 25‐W exercise (averaging ≥3 TD measurements), but not during unloaded cycling or at rest. Individual ΔCOs vary substantially and require critical interpretation to avoid CO misclassification. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. Correlation of Hemodynamic and Respiratory Parameters in Invasive Cardiopulmonary Exercise Testing (iCPET).
- Author
-
Habedank, Dirk, Obst, Anne, Heine, Alexander, Stubbe, Beate, and Ewert, Ralf
- Subjects
EXERCISE tests ,VENTILATION ,HEMODYNAMICS ,CARDIAC output ,EXERCISE intensity ,CARBON dioxide ,PULMONARY hypertension - Abstract
Background: Invasive cardiopulmonary exercise testing (iCPET) is an integral part in the advanced diagnostic workup of pulmonary hypertension (PH). Our study evaluated the relation between hemodynamic and respiratory parameters at two different resting conditions and two defined low exercise levels with a close synchronization of measurements in a broad variety of dyspnea patients. Subjects and methods: We included 146 patients (median age 69 years, range 22 to 85 years, n = 72 female) with dyspnea of uncertain origin. Invasive hemodynamic and gas exchange parameters were measured at rest, 45° upright position, unloaded cycling, 25 and 50 W exercise. All measurements were performed in a single RHC procedure. Results: Oxygen uptake (VO 2 /body mass) correlated significantly with cardiac index (all p ≤ 0.002) at every resting and exercise level and with every method of cardiac output measurement (thermodilution, method of Fick). Mean pulmonary arterial pressure (PAPmean) correlated with all respiratory parameters (respiratory rate, partial end-tidal pressures of oxygen and carbon dioxide [petCO 2 and petO 2 ], ventilation/carbon dioxide resp. oxygen ratio [VE/VCO 2 , VE/VO 2 ], and minute ventilation [VE], all p < 0.05). These correlations improved with increasing exercise levels from rest via unloaded cycling to 25 W. There was no correlation with right atrial or pulmonary arterial wedge pressure. Summary: In dyspnea patients of different etiologies, the cardiac index is closely linked to VO 2 at every level of rest and submaximal exercise. PAPmean is the only pressure that correlates with different respiratory parameters, but this correlation is highly significant and stable at rest, unloaded cycling and at 25 W. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. Continuous intravenous iloprost to revert treatment failure of first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension
- Author
-
Ewert, Ralf, Opitz, Christian F., Wensel, Roland, Winkler, Jörg, Halank, Michael, and Felix, Stephan B.
- Published
- 2007
- Full Text
- View/download PDF
10. Portopulmonary hypertension
- Author
-
Halank, Michael, Ewert, Ralf, Seyfarth, Hans-Juergen, and Hoeffken, Gert
- Published
- 2006
- Full Text
- View/download PDF
11. Successful switch from long-term intravenous iloprost to non-invasive combination therapy in idiopathic pulmonary arterial hypertension
- Author
-
Halank, Michael, Kolditz, Martin, Opitz, Christian, Hoeffken, Gert, and Ewert, Ralf
- Published
- 2006
- Full Text
- View/download PDF
12. Beurteilung der kardiopulmonalen Funktion und Belastungstests bei Patienten mit pulmonaler Hypertonie
- Author
-
Ewert, Ralf, Opitz, Christian F., Wensel, Roland, Halank, Michael, Winkler, Jörg, Lodziewski, Sven, and Felix, Stephan B.
- Published
- 2005
- Full Text
- View/download PDF
13. Value of Cardiopulmonary Exercise Testing in Prognostic Assessment of Patients with Interstitial Lung Diseases.
- Author
-
Stubbe, Beate, Ittermann, Till, Grieger, Anita, Walther, Charlotte, Gläser, Sven, and Ewert, Ralf
- Subjects
EXERCISE tests ,PROGNOSTIC tests ,PULMONARY hypertension ,INTERSTITIAL lung diseases ,NON-communicable diseases ,PULMONARY function tests ,BODY mass index - Abstract
Background: Interstitial lung disease (ILD) is associated with high rates of comorbidities and non-infectious lung disease mortality. Against this background, we aimed to evaluate the prognostic capacity of lung function and cardiopulmonary exercise testing (CPET) in patients with ILD. Materials and Methods: A total of 183 patients with diverse ILD entities were included in this monocentric analysis. Prediction models were determined using Cox regression models with age, sex, body mass index (BMI), and all parameters from pulmonary function testing and CPET. Kaplan–Meier curves were plotted for selected variables. Results: The median follow-up period was 3.0 ± 2.5 years. Arterial hypertension (57%) and pulmonary hypertension (38%) were the leading comorbidities. The Charlson comorbidity index score was 2 ± 2 points. The 3-year and 5-year survival rates were 68% and 50%, respectively. VO
2 peak (mL/kg/min or %pred.) was identified as a significant prognostic parameter in patients with ILD. The cut-off value for discriminating mortality was 61%. Conclusion: The present analyses consistently revealed the high prognostic power of VO2 peak %pred. and other parameters evaluating breathing efficacy (VÉ/VCO2 @AT und VÉ/VCO2 slope) in ILD patients. VO2 peak %pred., in contrast to the established prognostic values FVC %pred., DLCO/KCO %pred., and GAP, showed an even higher prognostic ability in all statistical models. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
14. Pulmonary Hypertension in Patients With COPD: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA).
- Author
-
Vizza, Carmine Dario, Hoeper, Marius M., Huscher, Doerte, Pittrow, David, Benjamin, Nicola, Olsson, Karen M., Ghofrani, H. Ardeschir, Held, Matthias, Klose, Hans, Lange, Tobias, Rosenkranz, Stephan, Dumitrescu, Daniel, Badagliacca, Roberto, Claussen, Martin, Halank, Michael, Vonk-Noordegraaf, Anton, Skowasch, Dirk, Ewert, Ralf, Gibbs, J. Simon R., and Delcroix, Marion
- Subjects
PULMONARY hypertension ,OBSTRUCTIVE lung diseases ,SURVIVAL rate ,PHOSPHODIESTERASE-5 inhibitors ,VASCULAR resistance ,ANTIHYPERTENSIVE agents ,RESEARCH ,RESEARCH methodology ,ACQUISITION of data ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,PHOSPHODIESTERASE inhibitors ,LONGITUDINAL method ,DISEASE complications - Abstract
Background: Pulmonary hypertension (PH) in COPD is a poorly investigated clinical condition.Research Question: Which factors determine the outcome of PH in COPD?Study Design and Methods: We analyzed the characteristics and outcome of patients enrolled in the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) with moderate or severe PH in COPD as defined during the 6th PH World Symposium who received medical therapy for PH and compared them with patients with idiopathic pulmonary arterial hypertension (IPAH).Results: The population included incident patients with moderate PH in COPD (n = 68), with severe PH in COPD (n = 307), and with IPAH (n = 489). Patients with PH in COPD were older, predominantly male, and treated mainly with phosphodiesterase-5 inhibitors. Despite similar hemodynamic impairment, patients with PH in COPD achieved a worse 6-min walking distance (6MWD) and showed a more advanced World Health Organization functional class (WHO FC). Transplant-free survival rates at 1, 3, and 5 years were higher in the IPAH group than in the PH in COPD group (IPAH: 94%, 75%, and 55% vs PH in COPD: 86%, 55%, and 38%; P = .004). Risk factors for poor outcomes in PH in COPD were male sex, low 6MWD, and high pulmonary vascular resistance (PVR). In patients with severe PH in COPD, improvements in 6MWD by ≥ 30 m or improvements in WHO FC after initiation of medical therapy were associated with better outcomes.Interpretation: Patients with PH in COPD were functionally more impaired and had a poorer outcome than patients with IPAH. Predictors of death in the PH in COPD group were sex, 6MWD, and PVR. Our data raise the hypothesis that some patients with severe PH in COPD may benefit from PH treatment. Randomized controlled studies are necessary to explore this hypothesis further.Trial Registry: ClinicalTrials.gov; No.: NCT01347216; URL: www.clinicaltrials.gov. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
15. Cardiopulmonary Exercise Testing in Combined Pulmonary Fibrosis and Emphysema.
- Author
-
Westhoff, Michael, Litterst, Patric, and Ewert, Ralf
- Subjects
PULMONARY hypertension diagnosis ,EXERCISE tests ,CARDIAC catheterization ,PULMONARY hypertension ,CARDIOPULMONARY system ,OXYGEN consumption ,AIRWAY (Anatomy) ,DIFFERENTIAL diagnosis ,RISK assessment ,PULMONARY function tests ,DESCRIPTIVE statistics ,PULMONARY fibrosis ,PULMONARY emphysema ,EARLY diagnosis ,DISEASE risk factors ,DISEASE complications - Abstract
Background: Combined pulmonary fibrosis and emphysema (CPFE) is a distinct entity among fibrosing lung diseases with a high risk for lung cancer and pulmonary hypertension (PH). Notably, concomitant PH was identified as a negative prognostic indicator that could help with early diagnosis to provide important information regarding prognosis. Objectives: The current study aimed to determine whether cardiopulmonary exercise testing (CPET) can be helpful in differentiating patients having CPFE with and without PH. Methods: Patients diagnosed with CPFE in 2 German cities (Hemer and Greifswald) over a period of 10 years were included herein. CPET parameters, such as peak oxygen uptake (peak VO
2 ), functional dead space ventilation (VDf /VT ), alveolar-arterial oxygen difference (AaDO2 ), arterial-end-tidal CO2 difference [P(a-ET)CO2 ] at peak exercise, and the minute ventilation-carbon dioxide production relationship (VE/VCO2 slope), were compared between patients with and without PH. Results: A total of 41 patients with CPET (22 with PH, 19 without PH) were analyzed. Right heart catheterization was performed in 15 of 41 patients without clinically relevant complications. Significant differences in peak VO2 (861 ± 190 vs. 1,397 ± 439 mL), VO2 /kg body weight/min (10.8 ± 2.6 vs. 17.4 ± 5.2 mL), peak AaDO2 (72.3 ± 7.3 vs. 46.3 ± 14.2 mm Hg), VE/VCO2 slope (70.1 ± 31.5 vs. 39.6 ± 9.6), and peak P(a-ET)tCO2 (13.9 ± 3.5 vs. 8.1 ± 3.6 mm Hg) were observed between patients with and without PH (p < 0.001). Patients with PH had significantly higher VDf /VT at rest, VT1 , and at peak exercise (65.6 ± 16.8% vs. 47.2 ± 11.6%; p < 0.001) than those without PH. A cutoff value of 44 for VE/VCO2 slope had a sensitivity and specificity of 94.7 and 72.7%, while a cutoff value of 11 mm Hg for P(a-ET)CO2 in combination with peak AaDO2 >60 mm Hg had a specificity and sensitivity of 95.5 and 84.2%, respectively. Combining peak AaDO2 >60 mm Hg with peak VO2 /body weight/min <16.5 mL/kg/min provided a sensitivity and specificity of 100 and 95.5%, respectively. Conclusion: This study provided initial data on CPET among patients having CPFE with and without PH. CPET can help noninvasively detect PH and identify patients at risk. AaDO2 at peak exercise, VE/VCO2 slope, peak P(a-ET)CO2 , and peak VO2 were parameters that had high sensitivity and, when combined, high specificity. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
16. Monotherapy in patients with pulmonary arterial hypertension at four German PH centres.
- Author
-
Stubbe, Beate, Seyfarth, Hans-Jürgen, Kleymann, Janina, Halank, Michael, Al Ghorani, Hussam, Obst, Anne, Desole, Susanna, Ewert, Ralf, and Opitz, Christian F.
- Subjects
PULMONARY hypertension ,CARDIOVASCULAR diseases risk factors ,COMORBIDITY ,DRUG utilization - Abstract
Background: Although combination therapy is the gold standard for patients with pulmonary arterial hypertension (PAH), some of these patients are still being treated with monotherapy.Methods: We conducted a retrospective analysis at four German PH centres to describe the prevalence and characteristics of patients receiving monotherapy.Results: We identified 131 incident PAH patients, with a mean age of 64 ± 13.8 years and a varying prevalence of comorbidities, cardiovascular risk factors and targeted therapy. As in other studies, the extent of prescribed PAH therapy varied with age and coexisting diseases, and younger, so-called "typical" PAH patients were more commonly treated early with combination therapy (48% at 4-8 months). In contrast, patients with multiple comorbidities or cardiovascular risk factors were more often treated with monotherapy (69% at 4-8 months). Survival at 12 months was not significantly associated with the number of PAH drugs used (single, dual, triple therapy) and was not different between "atypical" and "typical" PAH patients (89% vs. 85%).Conclusion: Although "atypical" PAH patients with comorbidities or a more advanced age are less aggressively treated with respect to combination therapy, the outcome of monotherapy in these patients appears to be comparable to that of dual or triple therapy in "typical" PAH patients. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
17. Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study.
- Author
-
Klose, Hans, Chin, Kelly M., Ewert, Ralf, Gall, Henning, Parambil, Joseph, Poch, David, Seyfarth, Hans-Jürgen, Axelsen, Lene N., Hsu Schmitz, Shu-Fang, Stein, Claudia, and Preston, Ioana R.
- Subjects
PULMONARY hypertension ,PHARMACOKINETICS ,BLOOD pressure - Abstract
Background: The oral IP receptor agonist selexipag is approved for the long-term treatment of pulmonary arterial hypertension (PAH). Treatment interruptions should be avoided due to the progressive nature of the disease. An intravenous (IV) formulation of selexipag was developed to provide a treatment option for short-term interruptions to oral selexipag. In this prospective, multicenter, open-label study, the safety, tolerability, and pharmacokinetics of temporarily switching between oral and IV selexipag were investigated (NCT03187678, ClinicalTrials.gov).Methods: PAH patients receiving stable oral selexipag doses were enrolled. Following three consecutive IV selexipag infusions patients resumed oral selexipag. Corresponding IV and oral doses were selected to achieve comparable exposure to the active metabolite of selexipag. Safety outcomes were monitored throughout, and pharmacokinetic samples were obtained after oral and IV administration.Results: All 20 patients completed the study. Fifteen patients had adverse events (AEs), most were mild, and none resulted in discontinuation. Headache was the most common AE throughout the study (four patients). Three serious AEs occurred in two patients with underlying comorbidities when oral dosing had resumed. There were no changes in WHO functional class for any patient and no clinically symptomatic changes in blood pressure were observed. Comparable exposure to the active metabolite of selexipag was demonstrated following corresponding oral and IV selexipag doses.Conclusions: Temporarily switching between corresponding doses of oral and IV selexipag was well-tolerated with no unexpected safety findings and comparable exposure to the active metabolite. Treatment with IV selexipag is a feasible option to bridge temporary oral selexipag treatment interruptions. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
18. Practical management of riociguat in patients with pulmonary arterial hypertension.
- Author
-
Halank, Michael, Tausche, Kristin, Grünig, Ekkehard, Ewert, Ralf, and Preston, Ioana R.
- Subjects
PULMONARY hypertension ,SYMPTOMS ,ADVERSE health care events - Abstract
Riociguat is one of several approved therapies available for patients with pulmonary arterial hypertension (PAH). Treatment should be initiated and monitored at an expert center by a physician experienced in treating PAH, and the dose adjusted in the absence of signs and symptoms of hypotension. In certain populations, including patients with hepatic or renal impairment, the elderly, and smokers, riociguat exposure may differ, and dose adjustments should therefore be made with caution according to the established scheme. Common adverse events are often easily managed, particularly if they are discussed before starting therapy. Combination therapy with riociguat and other PAH-targeted agents is feasible and generally well tolerated, although the coadministration of phosphodiesterase type 5 inhibitors (PDE5i) and riociguat is contraindicated. An open-label, randomized study is currently ongoing to assess whether patients who do not achieve treatment goals while receiving PDE5i may benefit from switching to riociguat. In this review, we provide a clinical view on the practical management of patients with PAH receiving riociguat, with a focus on the opinions and personal experience of the authors. The reviews of this paper are available via the supplemental material section. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
19. Right Heart Catheterization During Exercise in Patients with COPD—An Overview of Clinical Results and Methodological Aspects.
- Author
-
Ewert, Ralf, Heine, Alexander, Bollmann, Tom, Müller-Heinrich, Annegret, Gläser, Sven, and Opitz, Christian F.
- Subjects
- *
VENTRICULAR ejection fraction , *CARDIAC catheterization , *OBSTRUCTIVE lung diseases , *POSTURE , *EXERCISE - Abstract
While right heart catheterization (RHC) at rest is the gold standard to assess pulmonary hemodynamics in patients with chronic obstructive pulmonary disease (COPD) and pulmonary hypertension (PH), the invasive measurement of exercise hemodynamics is less well established in this group. Since exercise hemodynamics are increasingly recognized as important clinical information in patients with PH, our goal was to review the literature in this field to provide a basis for clinical use, further studies, and future recommendations. We identified 69 studies (published since 1968) reporting RHC data in 2819 patients with COPD, of whom 2561 underwent exercise testing. Few studies simultaneously measured gas exchange during exercise. Overall, these studies showed large variations in the patient populations and research questions studied and the methods and definitions employed. Despite these limitations, the data consistently demonstrated the presence of precapillary PH at rest in up to 38% of patients with COPD. With exercise, a relevant proportion of patients developed an abnormal hemodynamic response, depending on the definition used. Furthermore, some studies assessed right ventricular function during exercise and showed a blunted increase in right ventricular ejection fraction. Drug effects and the impact of interventional procedures were also studied. Again, due to large variations in the patients studied and the methods used, firm conclusions are difficult to derive. Despite the limitations of this dataset, several recommendations with respect to technical aspects (body position, exercise protocol, and data acquisition) can be inferred for this challenging patient population and may be helpful for further studies or recommendations. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
20. Predictive Capability of Cardiopulmonary and Exercise Parameters From Day 1 to 6 Months After Acute Pulmonary Embolism.
- Author
-
Habedank, Dirk, Opitz, Christian, Karhausen, Tim, Kung, Thomas, Steinke, Ingo, and Ewert, Ralf
- Subjects
BLOOD pressure ,CARBON dioxide ,CARDIAC output ,CARDIOPULMONARY system ,ECHOCARDIOGRAPHY ,EXERCISE physiology ,EXERCISE tests ,HEART ventricles ,PULMONARY embolism ,PULMONARY hypertension ,TIME ,OXYGEN consumption ,DESCRIPTIVE statistics - Abstract
We hypothesized that the slope of relation ventilation to carbon dioxide output (V'
E /V'CO2 -slope) could be predictive already during the very first days after submassive pulmonary embolism (PE) to right ventricular systolic pressure (RVsys by echocardiography) after 6 months. We evaluated 21 hemodynamically stable patients at admittance, at days 3, 7, 90, and 180 by cardiopulmonary exercise testing and echocardiography. V'E /V'CO2 -slope (48.4 ± 10.8) decreased within the first week (43.0 ± 9.8 at day 7) and normalized until follow-up at 6 months (35.0 ± 11.3; P < 10-4 ), p(a-ET) CO2 remained abnormal between days 1 and 3 (5.0 ± 3.9 to 6.7 ± 5.3 mmHg). RVsys declined from 41.7 ± 14.3 to 26.3±13.1 mmHg (P < 10-4 ) at 6 months. V'E /V'CO2 -slope (r²= 0.27; P < .02) and RVsys (r² = 0.28; P = .03) at day 7 correlated with RVsys at 6 months. p(a-ET) CO2 , p(a-ET) O2 , V'D /V'T were not related to RVsys after 6 months. RVsys 6 months after acute PE is positively correlated with the V'E /V'CO2 -slope at day 7. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
21. Safety and Efficacy of Immunoadsorption as an Add-On to Medical Treatment in Patients with Severe Idiopathic Pulmonary Arterial Hypertension.
- Author
-
Nagel, Christian, Ewert, Ralf, Egenlauf, Benjamin, Lehmkuhl, Hans B., Rosenkranz, Stephan, Benjamin, Nicola, Schwenger, Vedat, Herth, Felix J.F., and Grünig, Ekkehard
- Subjects
- *
PULMONARY hypertension treatment , *TREATMENT effectiveness , *AUTOANTIBODIES , *HEMODYNAMICS , *IMMUNOADSORPTION , *LONGITUDINAL method , *PLASMAPHERESIS , *PULMONARY hypertension , *SEVERITY of illness index - Abstract
Background: Despite optimized medical therapy, severe idiopathic pulmonary arterial hypertension (IPAH) is a devastating disease with a poor outcome. Autoantibodies have been detected in IPAH that can contribute to worsening of the disease. Objectives: The objective of this prospective, open-label, single-arm, multicenter trial was to evaluate the safety and efficacy of immunoadsorption (IA) as an add-on to optimized medical treatment for patients with IPAH. Methods: A total of 10 IPAH patients received IA over 5 days. Their clinical parameters, including hemodynamics measured by right heart catheter, were assessed at baseline and after 3 and 6 months. The primary endpoint was the change in pulmonary vascular resistance (PVR). Secondary endpoints included the change in 6-min walking distance, quality of life, safety, and plasma levels of IgG and autoantibodies. Results: The evaluation of the 10 IPAH patients (75% female; 51 ± 12 years; 166 ± 10 cm; WHO functional class III; 53% on combination therapy) revealed that IA was a safe procedure that efficiently removed IgG and autoantibodies from the circulation. After 3 months, the mean PVR improved significantly by 13.2% (p = 0.03) and the cardiac index improved by 13.1%, but no significant changes were found in 6-min walking distance. The quality of life physical functioning subscale score significantly improved after 6 months. The serious adverse events in 3 patients were possibly related to IA and included pneumonia, temporary disturbance Trial registration: ClinicalTrials.gov NCT01613287 (registered May 29, 2012). [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
22. Cardiopulmonary exercise testing for detecting pulmonary arterial hypertension in systemic sclerosis.
- Author
-
Dumitrescu, Daniel, Nagel, Christian, Kovacs, Gabor, Bollmann, Tom, Halank, Michael, Winkler, Jörg, Hellmich, Martin, Grünig, Ekkehard, Olschewski, Horst, Ewert, Ralf, and Rosenkranz, Stephan
- Subjects
SYSTEMIC scleroderma ,PULMONARY hypertension diagnosis ,CARDIOPULMONARY system physiology ,EXERCISE physiology ,CARDIAC catheterization ,RIGHT heart ventricle ,ALGORITHMS ,COMPARATIVE studies ,ECHOCARDIOGRAPHY ,EXERCISE tests ,LONGITUDINAL method ,VASCULAR resistance ,RESEARCH methodology ,MEDICAL cooperation ,PULMONARY hypertension ,RESEARCH ,RESEARCH evaluation ,EVALUATION research ,RECEIVER operating characteristic curves ,DISEASE complications ,DIAGNOSIS ,PHYSIOLOGY - Abstract
Objectives: Pulmonary arterial hypertension (PAH) is a devastating disease with limited survival and occurs as a frequent complication in patients with systemic sclerosis (SSc). A definite diagnosis of PAH is obtained by right heart catheterisation (RHC); however, the initial suspicion is raised by non-invasive methods. We assessed the diagnostic accuracy of key parameters derived from cardiopulmonary exercise testing (CPET) for detecting and ruling out SSc-associated PAH.Methods: In a multicentre setting, we prospectively evaluated 173 consecutive patients with SSc without known PAH, but with clinical suspicion of PAH. Each patient underwent CPET and RHC.Results: RHC identified PAH in 48 patients (27.8%), postcapillary pulmonary hypertension (PH) in 10 patients (5.8%) and ruled out PH in 115 patients (66.5%). CPET parameters correlated significantly with pulmonary haemodynamics. PeakVO2 and VE/VCO2 showed highest correlations with pulmonary arterial pressure, transpulmonary pressure gradient and pulmonary vascular resistance. Several parameters showed high sensitivity and specificity for PAH detection by receiver operating characteristic analysis. However, peakVO2 showed highest diagnostic accuracy (sensitivity 87.5%, specificity 74.8% at a threshold level of 13.8 mL/min/kg). A peakVO2 of >18.7 mL/kg/min was reached by 38/173 patients (22%) and excluded PAH in our cohort (negative predictive value 1.0). A nadir VE/VCO2 ratio of >45.5 showed a positive predictive value of 1.0. Diagnostic accuracy was highest in patients with low pulmonary arterial wedge pressure (<12 mm Hg). There were no study-related serious adverse events.Conclusions: CPET is a safe and valuable method in the non-invasive detection of SSc-associated PAH. It may be particularly beneficial for reducing unnecessary RHC procedures. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
23. Exercise Capacity Affects Quality of Life in Patients with Pulmonary Hypertension.
- Author
-
Halank, Michael, Einsle, Franziska, Lehman, Stephanie, Bremer, Hinrich, Ewert, Ralf, Wilkens, Heinrike, Meyer, F., Grünig, Ekkehard, Seyfarth, Hans-Jürgen, Kolditz, Martin, Wieder, Gesine, Höffken, Gert, and Köllner, Volker
- Subjects
HEMODYNAMICS ,MENTAL illness ,PULMONARY hypertension ,HEALTH surveys - Abstract
Background: The objective of this prospective study was to evaluate the impact of exercise capacity, mental disorders, and hemodynamics on quality-of-life (QoL) parameters in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). Methods: Sixty-three patients with invasively diagnosed PAH ( n = 48) or CTEPH ( n = 15) underwent a broad panel of assessments, including cardiopulmonary exercise testing (CPET), 6-minute walking distance (6-MWD), World Health Organization functional class (WHO-FC), and assessment of hemodynamics. QoL was evaluated by the 36-item Medical Outcome Study Short Form Health Survey Questionnaire (SF-36). Exercise capacity, hemodynamics, age, gender, and mental disorders (anxiety and depression) were assessed for association with QoL subscores by uni- and multivariate regression analyses. Results: Exercise capacity, WHO-FC, oxygen therapy, symptoms of right heart failure, right atrial pressure, and mental disorders were significantly associated with QoL ( p < 0.05). In the stepwise backward selection multivariate analysis, depression remained an independent parameter in seven of eight subscales of the SF-36. Furthermore, peak oxygen uptake (peakVO) during CPET, 6-MWD, anxiety, long-term oxygen therapy, right heart failure, and age remained independent factors for QoL. Hemodynamic parameters at rest did not independently correlate with any domain of the SF-36 QoL subscores. Conclusions: Mental disorders, exercise capacity, long-term oxygen therapy, right heart failure, and age play important role in the quality of life in patients with PAH and CTEPH. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
24. Pulmonary Hypertension in Patients with Idiopathic Pulmonary Fibrosis – The Predictive Value of Exercise Capacity and Gas Exchange Efficiency.
- Author
-
Gläser, Sven, Obst, Anne, Koch, Beate, Henkel, Beate, Grieger, Anita, Felix, Stephan B., Halank, Michael, Bruch, Leonhard, Bollmann, Tom, Warnke, Christian, Schäper, Christoph, and Ewert, Ralf
- Subjects
PULMONARY hypertension ,IDIOPATHIC pulmonary fibrosis ,EXERCISE ,PULMONARY gas exchange ,CARDIAC catheterization ,PULMONOLOGY - Abstract
Exercise capacity and survival of patients with IPF is potentially impaired by pulmonary hypertension. This study aims to investigate diagnostic and prognostic properties of gas exchange during exercise and lung function in IPF patients with or without pulmonary hypertension. In a multicentre setting, patients with IPF underwent right heart catheterization, cardiopulmonary exercise and lung function testing during their initial evaluation. Mortality follow up was evaluated. Seventy-three of 135 patients [82 males; median age of 64 (56; 72 years)] with IPF had pulmonary hypertension as assessed by right heart catheterization [median mean pulmonary arterial pressure 34 (27; 43) mmHg]. The presence of pulmonary hypertension was best predicted by gas exchange efficiency for carbon dioxide (cut off ≥152% predicted; area under the curve 0.94) and peak oxygen uptake (≤56% predicted; 0.83), followed by diffusing capacity. Resting lung volumes did not predict pulmonary hypertension. Survival was best predicted by the presence of pulmonary hypertension, followed by peak oxygen uptake [HR 0.96 (0.93; 0.98)]. Pulmonary hypertension in IPF patients is best predicted by gas exchange efficiency during exercise and peak oxygen uptake. In addition to invasively measured pulmonary arterial pressure, oxygen uptake at peak exercise predicts survival in this patient population. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
25. Respiratory muscle dysfunction in congestive heart failure—The role of pulmonary hypertension
- Author
-
Filusch, Arthur, Ewert, Ralf, Altesellmeier, Maike, Zugck, Christian, Hetzer, Roland, Borst, Mathias M., Katus, Hugo A., and Meyer, F. Joachim
- Subjects
- *
CONGESTIVE heart failure , *PULMONARY hypertension , *HEMODYNAMICS , *RESPIRATORY muscles , *VITAL capacity (Respiration) , *CARDIAC output - Abstract
Abstract: Background: Inspiratory muscle weakness has been described in patients with congestive heart failure (CHF), and only recently in patients with idiopathic pulmonary arterial hypertension. However, the relationship between pulmonary hemodynamics and respiratory muscle function has not been investigated in patients with CHF. Methods and results: In two tertial referral centers for CHF patients, 532 consecutive CHF patients (159 female, age 59±12years, NYHA I–IV) were studied by right heart catheterization, maximal inspiratory mouth occlusion pressure (Pimax) and pressure 0.1s after beginning of inspiration during tidal breathing at rest (P0.1). There was a significant correlation between Pimax and mean pulmonary artery pressure (PAPm) (r =−0.65, p =0.0023), mean pulmonary capillary wedge pressure (PCWPm) (r =−0.56; p =0.0018), PVR (r =−0.73; p =0.0031), and cardiac output (r =0.51; p =0.0022). Moreover, the ratio P0.1/Pimax showed a linear correlation with PAPm (r =0.54; p =0.0019), and with TPG (r =0.64; p =0.0014) respectively. Vital capacity was reduced in relation to increased PAPm (r =−0.54; p =0.0029). Pimax and P0.1/Pimax were independent from VC. Conclusions: This study provides the first evidence of a close relation between inspiratory muscle dysfunction, increased ventilatory drive and pulmonary hypertension in a large patient cohort with CHF. Pimax and P0.1 can easily be measured in clinical routine and might become an additional parameter for the non-invasive monitoring of the hemodynamic severity of disease. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
26. Reversibility of cachexia after bilateral lung transplantation
- Author
-
Habedank, Dirk, Ewert, Ralf, Hetzer, Roland, and Anker, Stefan D.
- Subjects
- *
CACHEXIA , *LUNG transplantation , *MORTALITY , *OBSTRUCTIVE lung diseases , *LONGITUDINAL method , *WEIGHT gain , *BODY mass index , *PATIENTS - Abstract
Abstract: Background: Cachexia is one of the terminating syndromes in pulmonary disease, and cachectic patients have an increased mortality even after lung transplantation (LTx). Our study assessed weight changes in cachectic patients after LTx compared to normal weight LTx recipients, and investigated differences in gender, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and primary pulmonary hypertension (PPH). Methods: We prospectively examined 46 patients before and serially 3, 6, 12 and 24 months after LTx (25 female, 21 male; median age at transplantation 46.9±13.9 years, n =17 COPD, n =8 CF, n =9 PPH, n =12 other origin). Patients were subgrouped as cachectic (BMI≤21 kg/m2, n =21), and non-cachectic (BMI >21, n =25). Results: Body weight increase was restricted to underweight patients: at 3 months (+2.1% vs. pre-transplant weight, p =0.28), 6 (+6.2%), 12 (+8.8%), and 24 months (+11.4%, all p ≤0.02). Non-cachectic patients suffered from weight loss at 3 months (−4.4%; p =0.02), and had non-significant weight gain at 6,12 and 24 months (+2.8 to 5.4%, all p >0.05). BMI pre LTx was correlated to weight gain after LTx (r =0.29 to 0.35; all p <0.05). Weight gain was not related to diagnosis (COPD, CF or PPH), gender or age. Conclusion: Weight gain after LTx is highest in underweight recipients and a continuous process from 3 months to 2 years after LTx. The weight gain is independent from the primary lung disease, and healing of this disease by LTx can make cachexia reversible. Weight increase after LTx is not affected by gender, immunosuppressive regimen, renal function before LTx, or age. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
27. Impact of pulmonary hypertension on gas exchange and exercise capacity in patients with pulmonary fibrosis.
- Author
-
Gläser, Sven, Noga, Oliver, Koch, Beate, Opitz, Christian F., Schmidt, Bernd, Temmesfeld, Bettina, Dörr, Marcus, Ewert, Ralf, and Schäper, Christoph
- Abstract
Summary: Pulmonary hypertension is a relevant interceding morbidity in patients with pulmonary fibrosis that has significant impact on exercise tolerance and outcome. The aim of this study was to further characterize the exercise intolerance, dyspnoea and ventilatory inefficiency of patients with pulmonary fibrosis in the presence or absence of pulmonary hypertension via cardiopulmonary exercise testing. Thirty-four patients underwent pulmonary function testing, symptom-limited exercise testing on a bicycle and dyspnoea evaluation according to the BORG scale. Pulmonary hypertension was assessed by echocardiography and in a subset of patient''s right heart catheterization. Sixteen of 34 patients with pulmonary fibrosis revealed pulmonary hypertension. While all study patients did not differ in lung functions and demographic characteristics, patients suffering from pulmonary hypertension showed a significantly impaired exercise tolerance and worsened ventilatory inefficiency. The extent of pulmonary artery pressure elevation impacted significantly on ventilatory inefficiency. In addition, the increased ventilatory requirements significantly influenced the extent of dyspnoea in patients with pulmonary hypertension. We conclude that pulmonary hypertension has a significant impact on exercise capacity and dyspnoea in patients with interstitial lung disease (ILD). The further impairment of exercise capacity as well as the extent of dyspnoea in patients with interceding PHT is attributable to a significantly impaired ventilatory inefficiency. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
28. Repetitive Dosing of Intravenous Levosimendan Improves Pulmonary Hemodynamics in Patients With Pulmonary Hypertension: Results of a Pilot Study.
- Author
-
Kleber, Franz X., Bollmann, Tom, Borst, Mathias M., Costard-Jäckle, Angelika, Ewert, Ralf, Kivikko, Matti, Petterson, Tiina, Pohjanjousi, Pasi, Sonntag, Steffen, and Wikström, Gerhard
- Subjects
PULMONARY hypertension treatment ,DRUG dosage ,HEMODYNAMICS ,VASCULAR resistance ,MYOCARDIAL depressants ,HYPERTENSION ,PATIENTS ,PHYSIOLOGY ,THERAPEUTICS - Abstract
The article focuses on the importance of repetitive dosing of intravenous levosimendan in patients with pulmonary hypertension. Pulmonary hypertension is characterized by an increase in pulmonary vascular resistance (PVR), resulting in right ventricular failure and even death. It finds out that repetitive dosing of levosimendan, a myocardial calcium sensitizer, indicates beneficial hemodynamic effects in lowering pulmonary hypertension, including a reduction in PVR.
- Published
- 2009
- Full Text
- View/download PDF
29. Influence of the incremental step size in work rate on exercise response and gas exchange in patients with pulmonary hypertension.
- Author
-
Gläser, Sven, Lodziewski, Sven, Koch, Beate, Opitz, Christian F., Völzke, Henry, and Ewert, Ralf
- Subjects
PULMONARY hypertension ,PULMONARY gas exchange ,ANAEROBIC threshold ,OXYGEN ,HYPERTENSION ,PATIENTS - Abstract
Background: Cardiopulmonary exercise testing (CPET) has become increasingly important as a routine procedure in daily clinical work. So far, it is generally accepted that an individualized exercise protocol with exercise duration of 6 to 12 minutes is preferable to assess maximal exercise performance. The aim of this study was to compare an individualized NYHA adapted exercise protocol with a fixed standard protocol in patients with severe pulmonary arterial hypertension. Methods: Twenty-two patients (17 female, 5 male; mean age 49 ± 14 yrs) underwent symptom limited CPET on a bicycle. On two consecutive days each subject performed a stepwise CPET according to a modified Jones protocol (16 Watt per minute stages) as well as an individualized NYHA adapted protocol with 5 or 10 Watt/min stages in a randomized order. Oxygen uptake at peak exercise (peakVO
2 ) and anaerobic threshold (VO2 AT), maximal ventilation (VE), breathing reserve (VE/MVV), ventilatory efficiency (VE vs. VCO2 slope), exercise time, maximal power and work rate were assessed and compared between both protocols. Results: Comparing both, adapted NYHA protocol and standardized Jones protocol, we found significant differences in maximal power (56.7 ± 19 W vs. 74 ± 18 W; p < 0.001) and exercise time (332 ± 107 sec. vs. 248 ± 72 sec.; p < 0.001). In contrast, no significant differences were obvious comparing both protocols concerning work rate, VE, VE/MVV, peakVO2 , VO2 AT and VE vs. VCO2 slope. Conclusion: Variations of incremental step size during CPET significantly affect exercise time and maximal power, whereas relevant parameters for clinical judgement and prognosis such as oxygen uptake, ventilation and ventilatory efficiency remain unchanged. These findings have practical implications for the exercise evaluation of patients with pulmonary hypertension. To reach maximal results for ventilation, oxygen uptake and gas exchange an individualization of incremental step size appears not to be mandatory. [ABSTRACT FROM AUTHOR]- Published
- 2008
- Full Text
- View/download PDF
30. Effect of Inhaled Iloprost during Off-Medication Time in Patients with Pulmonary Arterial Hypertension.
- Author
-
Mereles, Derliz, Ewert, Ralf, Lodziewski, Sven, Borst, Mathias M., Benz, Andreas, Olschewski, Horst, and Grünig, Ekkehard
- Subjects
- *
PULMONARY hypertension , *ILOPROST , *VASODILATION , *HEMODYNAMICS , *VASCULAR resistance - Abstract
Background: Iloprost is a stable prostacyclin analogue that is associated with a longer duration of vasodilatation and has been approved for inhalative use with 6 or 9 inhalations during the daytime and a night pause. It is not known if during the night pause rebound pulmonary hypertension occurs. The aim of this study was to assess the hemodynamics in iloprost-treated patients during the daytime and at night. Methods: We enrolled 5 adult patients (aged 45 ± 10 years) with idiopathic pulmonary arterial hypertension (IPAH) and chronic inhaled iloprost therapy for at least 12 months. Further medication remained unchanged during the study period. Hemodynamics were monitored by right heart catheterization. Results: After 30–60 min of nebulized iloprost, mean pulmonary arterial pressures (PAP) decreased from 68 ± 15 to 51 ± 18 mm Hg (p = 0.004). After 6 h off-medication sleeping time, mean PAP initially increased until 2 a.m. and decreased subsequently until wake-up time at 6 a.m. Mean PAP, cardiac index and pulmonary vascular resistance at night were not significantly different from the values during the day. Conclusions: In this study, patients with IPAH and chronic nebulized iloprost therapy did not reveal a rebound pulmonary hypertension during off-medication sleeping time. Copyright © 2007 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
31. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension.
- Author
-
Rubens, Christoph, Ewert, Ralf, Halank, Michael, Wensel, Roland, Orzechowski, Hans-Dieter, Schultheiss, Heinz-Peter, Hoeffken, Gert, Rubens, C, Ewert, R, Halank, M, Wensel, R, Orzechowski, H D, Schultheiss, H P, and Hoeffken, G
- Subjects
- *
PULMONARY hypertension , *ENDOTHELINS - Abstract
Study Objectives: Primary pulmonary hypertension (PPH) is a rare disease of unknown etiology that is characterized by a poor prognosis. This study was undertaken to investigate possible correlations between endothelin (ET)-1 and big ET-1 plasma levels and the severity of PPH.Patients: Sixteen consecutive patients with PPH were included.Interventions: Hemodynamics of patients with PPH were measured by right-heart catheterization, and a 6-min walk test was performed.Measurements: Plasma levels of the biologically active peptide ET-1 and its precursor big ET-1 were determined in blood samples from the pulmonary artery, peripheral artery, and peripheral vein by radioimmunoassay.Results: A strong correlation was shown between pulmonary vascular resistance, mean pulmonary artery pressure, cardiac output, cardiac index, 6-min walk data, and elevated plasma levels of big ET-1 as well as mature ET-1 plasma levels at all sites of blood sampling (p < 0.01 and p < 0.05, respectively).Conclusions: Levels of circulating ET-1 might become a prognostic marker for patients with PPH and serve as a tool for the selection of patients who may benefit from treatment with ET-receptor antagonists. [ABSTRACT FROM AUTHOR]- Published
- 2001
- Full Text
- View/download PDF
32. Digital Tracking of Physical Activity, Heart Rate, and Inhalation Behavior in Patients With Pulmonary Arterial Hypertension Treated With Inhaled Iloprost: Observational Study (VENTASTEP).
- Author
-
Stollfuss, Barbara, Richter, Manuel, Drömann, Daniel, Klose, Hans, Schwaiblmair, Martin, Gruenig, Ekkehard, Ewert, Ralf, Kirchner, Martin C, Kleinjung, Frank, Irrgang, Valeska, and Mueller, Christian
- Subjects
PULMONARY arterial hypertension ,INHALERS ,PHYSICAL activity ,HEART beat ,APPLE Watch ,QUALITY of life ,RESEARCH ,CLINICAL trials ,PULMONARY hypertension ,RESEARCH methodology ,MEDICAL cooperation ,EVALUATION research ,TREATMENT effectiveness ,COMPARATIVE studies ,VASODILATORS ,WALKING ,QUESTIONNAIRES ,INHALATION administration ,LONGITUDINAL method ,ILOPROST - Abstract
Background: Pulmonary arterial hypertension restricts the ability of patients to perform routine physical activities. As part of pulmonary arterial hypertension treatment, inhaled iloprost can be administered via a nebulizer that tracks inhalation behavior. Pulmonary arterial hypertension treatment is guided by intermittent clinical measurements, such as 6-minute walk distance, assessed during regular physician visits. Continuous digital monitoring of physical activity may facilitate more complete assessment of the impact of pulmonary arterial hypertension on daily life. Physical activity tracking with a wearable has not yet been assessed with simultaneous tracking of pulmonary arterial hypertension medication intake.Objective: We aimed to digitally track the physical parameters of patients with pulmonary arterial hypertension who were starting treatment with iloprost using a Breelib nebulizer. The primary objective was to investigate correlations between changes in digital physical activity measures and changes in traditional clinical measures and health-related quality of life over 3 months. Secondary objectives were to evaluate inhalation behavior, adverse events, and changes in heart rate and sleep quality.Methods: We conducted a prospective, multicenter observational study of adults with pulmonary arterial hypertension in World Health Organization functional class III who were adding inhaled iloprost to existing pulmonary arterial hypertension therapy. Daily distance walked, step count, number of standing-up events, heart rate, and 6-minute walk distance were digitally captured using smartwatch (Apple Watch Series 2) and smartphone (iPhone 6S) apps during a 3-month observation period (which began when iloprost treatment began). Before and at the end of the observation period (within 2 weeks), we also evaluated 6-minute walk distance, Borg dyspnea, functional class, B-type natriuretic peptide (or N-terminal pro-B-type natriuretic peptide) levels, health-related quality of life (EQ-5D questionnaire), and sleep quality (Pittsburgh Sleep Quality Index).Results: Of 31 patients, 18 were included in the full analysis (observation period: median 91.5 days, IQR 88.0 to 92.0). Changes from baseline in traditional and digital 6-minute walk distance were moderately correlated (r=0.57). Physical activity (daily distance walked: median 0.4 km, IQR -0.2 to 1.9; daily step count: median 591, IQR -509 to 2413) and clinical measures (traditional 6-minute walk distance: median 26 m, IQR 0 to 40) changed concordantly from baseline to the end of the observation period. Health-related quality of life showed little change. Total sleep score and resting heart rate slightly decreased. Distance walked and step count showed short-term increases after each iloprost inhalation. No new safety signals were identified (safety analysis set: n=30).Conclusions: Our results suggest that despite challenges, parallel monitoring of physical activity, heart rate, and iloprost inhalation is feasible in patients with pulmonary arterial hypertension and may complement traditional measures in guiding treatment; however, the sample size of this study limits generalizability.Trial Registration: ClinicalTrials.gov NCT03293407; https://clinicaltrials.gov/ct2/show/NCT03293407.International Registered Report Identifier (irrid): RR2-10.2196/12144. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
33. Myeloproliferative Diseases as Possible Risk Factor for Development of Chronic Thromboembolic Pulmonary Hypertension—A Genetic Study.
- Author
-
Eichstaedt, Christina A., Verweyen, Jeremias, Halank, Michael, Benjamin, Nicola, Fischer, Christine, Mayer, Eckhard, Guth, Stefan, Wiedenroth, Christoph B., Egenlauf, Benjamin, Harutyunova, Satenik, Xanthouli, Panagiota, Marra, Alberto M., Wilkens, Heinrike, Ewert, Ralf, Hinderhofer, Katrin, and Grünig, Ekkehard
- Subjects
DISEASE risk factors ,PULMONARY hypertension ,GENETIC testing ,DISEASE susceptibility ,PULMONARY aspergillosis ,GENETIC disorders - Abstract
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare disease which is often caused by recurrent emboli. These are also frequently found in patients with myeloproliferative diseases. While myeloproliferative diseases can be caused by gene defects, the genetic predisposition to CTEPH is largely unexplored. Therefore, the objective of this study was to analyse these genes and further genes involved in pulmonary hypertension in CTEPH patients. A systematic screening was conducted for pathogenic variants using a gene panel based on next generation sequencing. CTEPH was diagnosed according to current guidelines. In this study, out of 40 CTEPH patients 4 (10%) carried pathogenic variants. One patient had a nonsense variant (c.2071A>T p.Lys691*) in the BMPR2 gene and three further patients carried the same pathogenic variant (missense variant, c.1849G>T p.Val617Phe) in the Janus kinase 2 (JAK2) gene. The latter led to a myeloproliferative disease in each patient. The prevalence of this JAK2 variant was significantly higher than expected (p < 0.0001). CTEPH patients may have a genetic predisposition more often than previously thought. The predisposition for myeloproliferative diseases could be an additional risk factor for CTEPH development. Thus, clinical screening for myeloproliferative diseases and genetic testing may be considered also for CTEPH patients. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
34. Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry.
- Author
-
Kaemmerer, Harald, Gorenflo, Matthias, Huscher, Dörte, Pittrow, David, Apitz, Christian, Baumgartner, Helmut, Berger, Felix, Bruch, Leonhard, Brunnemer, Eva, Budts, Werner, Claussen, Martin, Coghlan, Gerry, Dähnert, Ingo, D'Alto, Michele, Delcroix, Marion, Distler, Oliver, Dittrich, Sven, Dumitrescu, Daniel, Ewert, Ralf, and Faehling, Martin
- Subjects
CONGENITAL heart disease ,PULMONARY hypertension ,EISENMENGER syndrome ,ENDOTHELIN receptors ,CARDIAC patients - Abstract
Introduction: Pulmonary hypertension (PH) is a common complication in patients with congenital heart disease (CHD), aggravating the natural, post-operative, or post-interventional course of the underlying anomaly. The various CHDs differ substantially in characteristics, functionality, and clinical outcomes among each other and compared with other diseases with pulmonary hypertension. Objective: To describe current management strategies and outcomes for adults with PH in relation to different types of CHD based on real-world data. Methods and results: COMPERA (Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension) is a prospective, international PH registry comprising, at the time of data analysis, >8200 patients with various forms of PH. Here, we analyzed a subgroup of 680 patients with PH due to CHD, who were included between 2007 and 2018 in 49 specialized centers for PH and/or CHD located in 11 European countries. At enrollment, the patients' median age was 44 years (67% female), and patients had either pre-tricuspid shunts, post-tricuspid shunts, complex CHD, congenital left heart or aortic disease, or miscellaneous other types of CHD. Upon inclusion, targeted therapies for pulmonary arterial hypertension (PAH) included endothelin receptor antagonists, PDE-5 inhibitors, prostacyclin analogues, and soluble guanylate cyclase stimulators. Eighty patients with Eisenmenger syndrome were treatment-naïve. While at inclusion the primary PAH treatment for the cohort was monotherapy (70% of patients), with 30% of the patients on combination therapy, after a median observation time of 45.3 months, the number of patients on combination therapy had increased significantly, to 50%. The use of oral anticoagulants or antiplatelets was dependent on the underlying diagnosis or comorbidities. In the entire COMPERA-CHD cohort, after follow-up and receiving targeted PAH therapy (n = 511), 91 patients died over the course of a 5-year follow up. The 5-year Kaplan–Meier survival estimate for CHD associated PH was significantly better than that for idiopathic PAH (76% vs. 54%; p < 0.001). Within the CHD associated PH group, survival estimates differed particularly depending on the underlying diagnosis and treatment status. Conclusions: In COMPERA-CHD, the overall survival of patients with CHD associated PH was dependent on the underlying diagnosis and treatment status, but was significantly better as than that for idiopathic PAH. Nevertheless, overall survival of patients with PAH due to CHD was still markedly reduced compared with survival of patients with other types of CHD, despite an increasing number of patients on PAH-targeted combination therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
35. Prognostic value of cardiopulmonary exercise testing in patients with systemic sclerosis.
- Author
-
Ewert, Ralf, Ittermann, Till, Habedank, Dirk, Held, Matthias, Lange, Tobias J., Halank, Michael, Winkler, Jörg, Gläser, Sven, Olschewski, Horst, and Kovacs, Gabor
- Subjects
EXERCISE tests ,SYSTEMIC scleroderma ,RHEUMATISM ,PULMONARY artery ,PULMONARY hypertension ,INTERSTITIAL lung diseases - Abstract
Background: Systemic sclerosis (SSc) is a severe rheumatic disease of the interstitial tissue, in which heart and lung involvement can lead to disease-specific mortality. Our study tests the hypothesis that in addition to established prognostic factors, cardiopulmonary exercise testing (CPET) parameters, particularly peak oxygen uptake (peakVO2) and ventilation/carbon dioxide (VE/VCO2)-slope, can predict survival in patients with SSc.Subjects and Methods: We retrospectively assessed 210 patients (80.9% female) in 6 centres over 10 years with pulmonary testing and CPET. Survival was analysed with Cox regression analysis (adjusted for age and gender) by age, comorbidity (Charlson-Index), body weight, body-mass index, extensive interstitial lung disease, pulmonary artery pressure (measured by echocardiography and invasively), and haemodynamic, pulmonary and CPET parameters.Results: Five- and ten-year survival of SSc patients was 93.8 and 86.9%, respectively. There was no difference in survival between patients with diffuse (dcSSc) and limited cutaneous manifestation (lcSSc; p = 0.3). Pulmonary and CPET parameters were significantly impaired. Prognosis was worst for patients with pulmonary hypertension (p = 0.007), 6-min walking distance < 413 m (p = 0.003), peakVO2 < 15.6 mL∙kg- 1∙min- 1, and VE/VCO2-slope > 35. Age (hazard ratio HR = 1.23; 95% confidence interval CI: 1.14;1.41), VE/VCO2-slope (HR = 0.9; CI 0.82;0.98), diffusion capacity (Krogh factor, HR = 0.92; CI 0.86;0.98), forced vital capacity (FVC, HR = 0.91; CI 0.86;0.96), and peakVO2 (HR = 0.87; CI 0.81;0.94) were significantly linked to survival in multivariate analyses (Harrell's C = 0.95). This is the first large study with SSc patients that demonstrates the prognostic value of peakVO2 < 15.6 mL∙kg- 1∙min- 1 (< 64.5% of predicted peakVO2) and VE/VCO2-slope > 35. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
36. Positive Vasoreactivity Testing in Pulmonary Arterial Hypertension: Therapeutic Consequences, Treatment Patterns, and Outcomes in the Modern Management Era.
- Author
-
Gerhardt, Felix, Fiessler, Eva, Olsson, Karen M., Kayser, Moritz Z., Kovacs, Gabor, Gall, Henning, Ghofrani, H. Ardeschir, Eslam, Roza Badr, Lang, Irene M., Benjamin, Nicola, Grünig, Ekkehard, Halank, Michael, Lange, Tobias J., Ulrich, Silvia, Leuchte, Hanno, Held, Matthias, Klose, Hans, Ewert, Ralf, Wilkens, Heinrike, and Pizarro, Carmen
- Subjects
- *
PULMONARY arterial hypertension , *BRAIN natriuretic factor , *RETENTION of urine , *CALCIUM antagonists , *PULMONARY hypertension , *PULMONARY artery , *CARDIAC catheterization - Abstract
BACKGROUND: Among patients with pulmonary arterial hypertension (PAH), acute vasoreactivity testing during right heart catheterization may identify acute vasoresponders, for whom treatment with high-dose calcium channel blockers (CCBs) is recommended. However, long-term outcomes in the current era remain largely unknown. We sought to evaluate the implications of acute vasoreactivity response for long-term response to CCBs and other outcomes. METHODS: Patients diagnosed with PAH between January 1999 and December 2018 at 15 pulmonary hypertension centers were included and analyzed retrospectively. In accordance with current guidelines, acute vasoreactivity response was defined by a decrease of mean pulmonary artery pressure by ≥10 mm Hg to reach <40 mm Hg, without a decrease in cardiac output. Long-term response to CCBs was defined as alive with unchanged initial CCB therapy with or without other initial PAH therapy and World Health Organization functional class I/II and/or low European Society of Cardiology/European Respiratory Society risk status at 12 months after initiation of CCBs. Patients were followed for up to 5 years; clinical measures, outcome, and subsequent treatment patterns were captured. RESULTS: Of 3702 patients undergoing right heart catheterization for PAH diagnosis, 2051 had idiopathic, heritable, or drug-induced PAH, of whom 1904 (92.8%) underwent acute vasoreactivity testing. A total of 162 patients fulfilled acute vasoreactivity response criteria and received an initial CCB alone (n=123) or in combination with another PAH therapy (n=39). The median follow-up time was 60.0 months (interquartile range, 30.8--60.0), during which overall survival was 86.7%. At 12 months, 53.2% remained on CCB monotherapy, 14.7% on initial CCB plus another initial PAH therapy, and the remaining patients had the CCB withdrawn and/or PAH therapy added. CCB long-term response was found in 54.3% of patients. Five-year survival was 98.5% in long-term responders versus 73.0% in nonresponders. In addition to established vasodilator responder criteria, pulmonary artery compliance at acute vasoreactivity testing, low risk status and NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels at early follow-up correlated with long-term response and predicted survival. CONCLUSIONS: Our data display heterogeneity within the group of vasoresponders, with a large subset failing to show a sustained satisfactory clinical response to CCBs. This highlights the necessity for comprehensive reassessment during early follow-up. The use of pulmonary artery compliance in addition to current measures may better identify those likely to have a good long-term response. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
37. Impaired peripheral endothelial function in severe idiopathic pulmonary hypertension correlates with the pulmonary vascular response to inhaled iloprost.
- Author
-
Wolff, Birger, Lodziewski, Sven, Bollmann, Tom, Opitz, Christian F., and Ewert, Ralf
- Subjects
HYPERTENSION ,ENDOTHELIUM ,PULMONARY hypertension ,BLOOD vessels - Abstract
Background: Pulmonary endothelial function is known to be impaired in subjects with idiopathic pulmonary arterial hypertension (IPAH), but peripheral endothelial dysfunction and its predictive value for pulmonary vasoreactivity have not been previously investigated. Methods: Measurements of peripheral endothelium-dependent and endothelium-independent vasoreactivity using flow-mediated dilation (FMD) and nitroglycerin-mediated dilation of the brachial artery were performed in 18 patients with severe IPAH (15 women; mean age 50 years [95% confidence interval 46-55 years], mean pulmonary artery pressure [PAP] 51 mm Hg [43-59 mm Hg], pulmonary vascular resistance [PVR] 1239 dyn s cm
−5 [861-1618 dyn s cm−5 ] at baseline) and in 36 age- and sex-matched controls. In patients with IPAH, acute pulmonary vasoreactivity was measured as pulmonary vascular response to inhaled iloprost (PVRII) during pulmonary catheterization. Results: Compared to controls, patients with IPAH demonstrated impaired peripheral endothelial function (FMD, 0.19 [0.07-0.31] vs 0.38 [0.30-0.44] mm among controls; P =.002). No such impairment was observed for nitroglycerin-mediated dilation (0.34 [0.23-0.46] vs 0.36 [0.20-0.51] mm among controls; P = .679). Among patients with IPAH, iloprost lowered mean PAP by 8.2 mm Hg (2.0-14.5 mm Hg) (P = .001) and PVR by 395 dyn s cm−5 (109-680 dyn s cm−5 ) (P < .001). Subsequent analysis of the association between peripheral endothelial function and PVRII disclosed a correlation of FMD with the percent decrease in mean PAP (r = .65, P = .003) and PVR (r = 0.67, P = .002), in which patients with IPAH with the greatest PVRII also exhibited the highest FMD values. Conclusions: Idiopathic pulmonary arterial hypertension is associated with peripheral endothelial dysfunction. Peripheral endothelium-dependent vasoreactivity correlates with the PVRII. It remains to be established if FMD has the potential as a clinical tool for noninvasive estimation of pulmonary vasoreactivity in IPAH. [Copyright &y& Elsevier]- Published
- 2007
- Full Text
- View/download PDF
38. Risk stratification and response to therapy in patients with pulmonary arterial hypertension and comorbidities: A COMPERA analysis.
- Author
-
Rosenkranz, Stephan, Pausch, Christine, Coghlan, John G., Huscher, Doerte, Pittrow, David, Grünig, Ekkehard, Staehler, Gerd, Vizza, Carmine Dario, Gall, Henning, Distler, Oliver, Delcroix, Marion, Ghofrani, Hossain A., Ewert, Ralf, Kabitz, Hans-Joachim, Skowasch, Dirk, Behr, Juergen, Milger, Katrin, Halank, Michael, Wilkens, Heinrike, and Seyfarth, Hans-Jürgen
- Subjects
- *
PULMONARY arterial hypertension , *BRAIN natriuretic factor , *COMORBIDITY , *TREATMENT effectiveness , *OLDER patients , *PULMONARY hypertension - Abstract
A diagnosis of idiopathic pulmonary arterial hypertension (IPAH) is frequently made in elderly patients who present with comorbidities, especially hypertension, coronary heart disease, diabetes mellitus, and obesity. It is unknown to what extent the presence of these comorbidities affects the response to PAH therapies and whether risk stratification predicts outcome in patients with comorbidities. We assessed the database of COMPERA, a European pulmonary hypertension registry, to determine changes after initiation of PAH therapy in WHO functional class (FC), 6-minute walking distance (6MWD), brain natriuretic peptide (BNP) or N-terminal fragment of probrain natriuretic peptide (NT-pro-BNP), and mortality risk assessed by a 4-strata model in patients with IPAH and no comorbidities, 1-2 comorbidities and 3-4 comorbidities. The analysis was based on 1,120 IPAH patients (n = 208 [19%] without comorbidities, n = 641 [57%] with 1-2 comorbidities, and n = 271 [24%] with 3-4 comorbidities). Improvements in FC, 6MWD, BNP/NT-pro-BNP, and mortality risk from baseline to first follow-up were significantly larger in patients with no comorbidities than in patients with comorbidities, while they were not significantly different in patients with 1-2 and 3-4 comorbidities. The 4-strata risk tool predicted survival in patients without comorbidities as well as in patients with 1-2 or 3-4 comorbidities. Our data suggest that patients with IPAH and comorbidities benefit from PAH medication with improvements in FC, 6MWD, BNP/NT-pro-BNP, and mortality risk, albeit to a lesser extent than patients without comorbidities. The 4-strata risk tool predicted outcome in patients with IPAH irrespective of the presence of comorbidities. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
39. Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry.
- Author
-
Hoeper, Marius M., Pausch, Christine, Grünig, Ekkehard, Klose, Hans, Staehler, Gerd, Huscher, Doerte, Pittrow, David, Olsson, Karen M., Vizza, Carmine Dario, Gall, Henning, Benjamin, Nicola, Distler, Oliver, Opitz, Christian, Gibbs, J. Simon R., Delcroix, Marion, Ghofrani, H. Ardeschir, Rosenkranz, Stephan, Ewert, Ralf, Kaemmerer, Harald, and Lange, Tobias J.
- Subjects
- *
CLUSTER analysis (Statistics) , *PULMONARY hypertension , *CORONARY disease , *HIERARCHICAL clustering (Cluster analysis) , *CARBON monoxide - Abstract
The term idiopathic pulmonary arterial hypertension (IPAH) is used to categorize patients with pre-capillary pulmonary hypertension of unknown origin. There is considerable variability in the clinical presentation of these patients. Using data from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension, we performed a cluster analysis of 841 patients with IPAH based on age, sex, diffusion capacity of the lung for carbon monoxide (DLCO; <45% vs ≥45% predicted), smoking status, and presence of comorbidities (obesity, hypertension, coronary heart disease, and diabetes mellitus). A hierarchical agglomerative clustering algorithm was performed using Ward's minimum variance method. The clusters were analyzed in terms of baseline characteristics; survival; and response to pulmonary arterial hypertension (PAH) therapy, expressed as changes from baseline to follow-up in functional class, 6-minute walking distance, cardiac biomarkers, and risk. Three clusters were identified: Cluster 1 (n = 106; 12.6%): median age 45 years, 76% females, no comorbidities, mostly never smokers, DLCO ≥45%; Cluster 2 (n = 301; 35.8%): median age 75 years, 98% females, frequent comorbidities, no smoking history, DLCO mostly ≥45%; and Cluster 3 (n = 434; 51.6%): median age 72 years, 72% males, frequent comorbidities, history of smoking, and low DLCO. Patients in Cluster 1 had a better response to PAH treatment than patients in the 2 other clusters. Survival over 5 years was 84.6% in Cluster 1, 59.2% in Cluster 2, and 42.2% in Cluster 3 (unadjusted p < 0.001 for comparison between all groups). The population of patients diagnosed with IPAH is heterogenous. This cluster analysis identified distinct phenotypes, which differed in clinical presentation, response to therapy, and survival. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
40. Intravenous treprostinil as an add-on therapy in patients with pulmonary arterial hypertension.
- Author
-
Olsson, Karen M., Richter, Manuel J., Kamp, Jan C., Gall, Henning, Heine, Alexander, Ghofrani, Hossein-Ardeshir, Fuge, Jan, Ewert, Ralf, and Hoeper, Marius M.
- Subjects
- *
PULMONARY hypertension , *RISK assessment , *FOLLOW-up studies (Medicine) , *CONFIDENCE intervals , *THERAPEUTICS - Abstract
In patients with pulmonary arterial hypertension who have an insufficient response to oral or inhaled therapies, current guidelines recommend the use of parenteral prostacyclin analogues, although the efficacy of this approach is unknown. This retrospective multicenter study evaluated patients with pulmonary arterial hypertension who received intravenous treprostinil as an add-on therapy. The risk at baseline and follow-up (6–12 months after the initiation of treprostinil) was classified as low, intermediate, or high according to current recommendations. The outcome was measured as transplant-free survival after the initiation of treprostinil therapy. A total of 126 patients were analyzed, almost all of them pre-treated with combinations of other pulmonary arterial hypertension medications. Before the initiation of intravenous treprostinil, 2 (2%) patients had a low-risk profile; 100 (79%), an intermediate-risk profile; and 24 (19%), a high-risk profile. At follow-up, 24 (19%) patients were classified as low-risk. These patients had a 5-year transplant-free survival rate >90%. In contrast, patients who remained at intermediate or high risk had transplant-free survival rates of 76%, 43%, and 28% at 1, 3, and 5 years, respectively. Failure to reach a low risk at follow-up was an independent predictor of transplant-free survival (hazard ratio, 9.25; 95% confidence interval, 1.20–71.60; p = 0.033 1). Risk assessment at 6–12 months after the initiation of add-on intravenous treprostinil in patients with an insufficient response to nonparenteral treatments allows the prediction of transplant-free survival over the ensuing years. Achieving a low-risk profile is associated with excellent outcomes, whereas mortality is high in patients who remain at intermediate or high risk. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
41. Risk stratification strategy and assessment of disease progression in patients with pulmonary arterial hypertension: Updated Recommendations from the Cologne Consensus Conference 2018.
- Author
-
Leuchte, Hanno H., ten Freyhaus, Henrik, Gall, Henning, Halank, Michael, Hoeper, Marius M., Kaemmerer, Harald, Kähler, Christian, Riemekasten, Gabriela, Ulrich, Silvia, Schwaiblmair, Martin, and Ewert, Ralf
- Abstract
Abstract In the summer of 2016, delegates from the German Respiratory Society, the German Society of Cardiology and the German Society of Pediatric Cardiology met in Cologne, Germany, to define consensus-based practice recommendations for the management of patients with pulmonary arterial hypertension (PAH). These recommendations were built on the 2015 European Pulmonary Hypertension guidelines and included new evidence, where available, and were last updated in the spring of 2018. This article focusses on the proposed risk stratification and assessment of disease progression in patients with pulmonary arterial hypertension (PAH), covering 3 parts: In part 1, methods and markers that are recommended to assess severity and progression of PAH are discussed and commented. These updated comments incorporate most recent data as well as challenges arising from the variability of phenotypes of PAH patients with increasing cardiopulmonary comorbidities. In part 2, the proposed ESC/ERS risk stratification strategy is discussed, together with a review of the recent validation studies from different European registries. Finally, in part 3, the working group of the Cologne Consensus Conference provides recommendations on how risk assessment may be implemented in routine clinical practice and may serve clinical decision making. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
42. Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018.
- Author
-
Hoeper, Marius M., Apitz, Christian, Grünig, Ekkehard, Halank, Michael, Ewert, Ralf, Kaemmerer, Harald, Kabitz, Hans-Joachim, Kähler, Christian, Klose, Hans, Leuchte, Hanno, Ulrich, Silvia, Olsson, Karen M., Distler, Oliver, Rosenkranz, Stephan, and Ghofrani, H. Ardeschir
- Abstract
Abstract In the summer of 2016, delegates from the German Respiratory Society, the German Society of Cardiology and the German Society of Pediatric Cardiology met in Cologne, Germany, to define consensus-based practice recommendations for the management of patients with pulmonary arterial hypertension (PAH). These recommendations were built on the 2015 European Pulmonary Hypertension guidelines and included new evidence, where available. The treatment algorithm for PAH was modified based on the observation that there are now many patients diagnosed with IPAH who are at an advanced age and have significant cardiopulmonary comorbidities. For patients newly diagnosed with classic forms of PAH, i.e. younger patients without significant cardiopulmonary comorbidities, the consensus-based recommendation was to use initial combination therapy as the standard approach. The use of monotherapies was no longer considered appropriate in such patients. The choice of treatment strategies should be based on the risk assessment as proposed in the European guidelines. In patients presenting with a low or intermediate risk, oral combination therapy with endothelin receptor antagonists and phosphodiesterase-5 inhibitors or soluble guanylate cyclase stimulators, respectively, should be used. In high-risk patients, triple combination therapy including a subcutaneous or intravenous prostacyclin analogue should be considered. For patients who suffer from PAH and significant cardiopulmonary comorbidities, initial monotherapy is recommended and the use of combination therapies should be considered on an individual basis. The latter recommendations are based on the scarcity of evidence supporting the use of combination therapy and the higher risk of drug-related adverse events in such patients. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
43. Anticoagulation and Survival in Pulmonary Arterial Hypertension.
- Author
-
Olsson, Karen M., Delcroix, Marion, Ghofrani, H. Ardeschir, Tiede, Henning, Huscher, Doerte, Speich, Rudolf, Grtinig, Ekkehard, Staehler, Gerd, Rosenkranz, Stephan, Halank, Michael, Held, Matthias, Lange, Tobias J., Behr, Juergen, Klose, Hans, Claussen, Martin, Ewert, Ralf, Opitz, Christian F., Vizza, C. Dario, Scelsi, Laura, and Vonk-Noordegraaf, Anton
- Subjects
- *
PULMONARY hypertension , *ANTICOAGULANTS , *CONFIDENCE intervals , *CLINICAL trials ,PULMONARY artery diseases - Abstract
Background--For almost 30 years, anticoagulation has been recommended for patients with idiopathic pulmonary arterial hypertension (1PAH). Supporting evidence, however, is limited, and it is unclear whether this recommendation is still justified in the modem management era and whether it should be extended to patients with other forms of pulmonary arterial hypertension (PAH). Methods and Results--We analyzed data from Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA), an ongoing European pulmonary hypertension registry. Survival rates of patients with IPAH and other forms of PAH were compared by the use of anticoagulation. The sample consisted of 1283 consecutively enrolled patients with newly diagnosed PAH. Anticoagulation was used in 66% of 800 patients with IPAH and in 43% of 483 patients with other forms of PAH. In patients with IPAH, there was a significantly better 3-year survival (P=0.006) in patients on anticoagulation compared with patients who never received anticoagulation, albeit the patients in the anticoagulation group had more severe disease at baseline. The survival difference at 3 years remained statistically significant (P=0.017) in a matched-pair analysis of n=336 IPAH patients. The beneficial effect of anticoagulation on survival of IPAH patients was confirmed by Cox multivariable regression analysis (hazard ratio, 0.79; 95% confidence interval, 0.664).94). In contrast, the use of anticoagulants was not associated with a survival benefit in patients with other forms of PAH. Conclusions--The present data suggest that the use of anticoagulation is associated with a survival benefit in patients with IPAH, supporting current treatment recommendations. The evidence remains inconclusive for other forms of PAH. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
44. Complications of Right Heart Catheterization Procedures in Patients With Pulmonary Hypertension in Experienced Centers
- Author
-
Hoeper, Marius M., Lee, Stephen H., Voswinckel, Robert, Palazzini, Massimiliano, Jais, Xavier, Marinelli, Alessandro, Barst, Robyn J., Ghofrani, Hossein A., Jing, Zhi-Cheng, Opitz, Christian, Seyfarth, Hans-Juergen, Halank, Michael, McLaughlin, Vallerie, Oudiz, Ronald J., Ewert, Ralf, Wilkens, Heinrike, Kluge, Stefan, Bremer, Hinrich-Cordt, Baroke, Eva, and Rubin, Lewis J.
- Subjects
- *
CARDIAC catheterization , *PULMONARY hypertension , *ANGIOGRAPHY , *HYPERTENSION - Abstract
Objectives: This study sought to assess the risks associated with right heart catheter procedures in patients with pulmonary hypertension. Background: Right heart catheterization, pulmonary vasoreactivity testing, and pulmonary angiography are established diagnostic tools in patients with pulmonary hypertension, but the risks associated with these procedures have not been systematically evaluated in a multicenter study. Methods: We performed a multicenter 5-year retrospective and 6-month prospective evaluation of serious adverse events related to right heart catheter procedures in patients with pulmonary hypertension, as defined by a mean pulmonary artery pressure >25 mm Hg at rest, undergoing right heart catheterization with or without pulmonary vasoreactivity testing or pulmonary angiography. Results: During the retrospective period, 5,727 right heart catheter procedures were reported, and 1,491 were reported from the prospective period, for a total of 7,218 right heart catheter procedures performed. The results from the retrospective and the prospective analyses were almost identical. The overall number of serious adverse events was 76 (1.1%, 95% confidence interval 0.8% to 1.3%). The most frequent complications were related to venous access (e.g., hematoma, pneumothorax), followed by arrhythmias and hypotensive episodes related to vagal reactions or pulmonary vasoreactivity testing. The vast majority of these complications were mild to moderate in intensity and resolved either spontaneously or after appropriate intervention. Four fatal events were recorded in association with any of the catheter procedures, resulting in an overall procedure-related mortality of 0.055% (95% confidence interval 0.01% to 0.099%). Conclusions: When performed in experienced centers, right heart catheter procedures in patients with pulmonary hypertension are associated with low morbidity and mortality rates. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
45. Pulmonary hypertension: Hemodynamic evaluation. Updated Recommendations of the Cologne Consensus Conference 2011
- Author
-
Opitz, Christian F., Blindt, Rüdiger, Blumberg, Friedrich, Borst, Mathias M., Bruch, Leonhard, Leuchte, Hanno H., Lichtblau, Mona, Nagel, Christian, Peters, Klaus, Rosenkranz, Stephan, Schranz, Dietmar, Skowasch, Dirk, Tiede, Henning, Weil, Joachim, and Ewert, Ralf
- Subjects
- *
PULMONARY hypertension diagnosis , *LUNG disease treatment , *GUIDELINES , *CARDIOLOGY , *HEMODYNAMICS , *PROFESSIONAL associations - Abstract
Abstract: The 2009 European Guidelines on Diagnosis and Treatment of Pulmonary Hypertension have been adopted for Germany. The guidelines contain detailed recommendations for the diagnosis of pulmonary hypertension. However, the practical implementation of the European Guidelines in Germany requires the consideration of several country-specific issues and already existing novel data. This requires a detailed commentary to the guidelines, and in some aspects an update already appears necessary. In June 2010, a Consensus Conference organized by the PH working groups of the German Society of Cardiology (DGK), the German Society of Respiratory Medicine (DGP) and the German Society of Pediatric Cardiology (DGPK) was held in Cologne, Germany. This conference aimed to solve practical and controversial issues surrounding the implementation of the European Guidelines in Germany. To this end, a number of working groups was initiated, one of which was specifically dedicated to the invasive hemodynamic evaluation of pulmonary hypertension. This manuscript describes in detail the results and recommendations of the working group which were last updated in October 2011. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.